BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27673363)

  • 1. Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Huang J; Mondul AM; Weinstein SJ; Koutros S; Derkach A; Karoly E; Sampson JN; Moore SC; Berndt SI; Albanes D
    Br J Cancer; 2016 Oct; 115(9):1087-1095. PubMed ID: 27673363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.
    Trabert B; Eldridge RC; Pfeiffer RM; Shiels MS; Kemp TJ; Guillemette C; Hartge P; Sherman ME; Brinton LA; Black A; Chaturvedi AK; Hildesheim A; Berndt SI; Safaeian M; Pinto L; Wentzensen N
    Int J Cancer; 2017 Feb; 140(3):600-610. PubMed ID: 27770434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study.
    Mondul AM; Moore SC; Weinstein SJ; Karoly ED; Sampson JN; Albanes D
    Int J Cancer; 2015 Nov; 137(9):2124-32. PubMed ID: 25904191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of serum metabolites and colorectal cancer risk.
    Cross AJ; Moore SC; Boca S; Huang WY; Xiong X; Stolzenberg-Solomon R; Sinha R; Sampson JN
    Cancer; 2014 Oct; 120(19):3049-57. PubMed ID: 24894841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry.
    Nishiumi S; Kobayashi T; Kawana S; Unno Y; Sakai T; Okamoto K; Yamada Y; Sudo K; Yamaji T; Saito Y; Kanemitsu Y; Okita NT; Saito H; Tsugane S; Azuma T; Ojima N; Yoshida M
    Oncotarget; 2017 Mar; 8(10):17115-17126. PubMed ID: 28179577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor.
    Huang J; Mondul AM; Weinstein SJ; Karoly ED; Sampson JN; Albanes D
    Oncotarget; 2017 Jul; 8(28):45190-45199. PubMed ID: 28423352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolite Profiles of the Serum of Patients with Non-Small Cell Carcinoma.
    Mazzone PJ; Wang XF; Beukemann M; Zhang Q; Seeley M; Mohney R; Holt T; Pappan KL
    J Thorac Oncol; 2016 Jan; 11(1):72-8. PubMed ID: 26762741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Grubb RL; Pinsky P; Prorok PC; Andriole GL
    Eur Urol; 2015 Oct; 68(4):545-6. PubMed ID: 25959167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective serum metabolomic profiling of lethal prostate cancer.
    Huang J; Mondul AM; Weinstein SJ; Derkach A; Moore SC; Sampson JN; Albanes D
    Int J Cancer; 2019 Dec; 145(12):3231-3243. PubMed ID: 30779128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Byrd DA; Zouiouich S; Karwa S; Li XS; Wang Z; Sampson JN; Loftfield E; Huang WY; Hazen SL; Sinha R
    Cancer; 2024 Jun; 130(11):1982-1990. PubMed ID: 38285606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Andriole GL
    Recent Results Cancer Res; 2014; 202():53-7. PubMed ID: 24531777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. White blood cell DNA methylation and risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).
    Sturgeon SR; Pilsner JR; Arcaro KF; Ikuma K; Wu H; Kim SM; Chopra-Tandon N; Karpf AR; Ziegler RG; Schairer C; Balasubramanian R; Reckhow DA
    Breast Cancer Res; 2017 Aug; 19(1):94. PubMed ID: 28821281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
    Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
    J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A quantitative multimodal metabolomic assay for colorectal cancer.
    Farshidfar F; Kopciuk KA; Hilsden R; McGregor SE; Mazurak VC; Buie WD; MacLean A; Vogel HJ; Bathe OF
    BMC Cancer; 2018 Jan; 18(1):26. PubMed ID: 29301511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
    Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
    Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival.
    Huang J; Weinstein SJ; Moore SC; Derkach A; Hua X; Mondul AM; Sampson JN; Albanes D
    J Gerontol A Biol Sci Med Sci; 2019 May; 74(6):853-859. PubMed ID: 29878065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case control study of sarcosine as an early prostate cancer detection biomarker.
    Ankerst DP; Liss M; Zapata D; Hoefler J; Thompson IM; Leach RJ
    BMC Urol; 2015 Oct; 15():99. PubMed ID: 26429735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 102 Correlations between Serum Metabolites and Habitual Diet in a Metabolomics Study of the Prostate, Lung, Colorectal, and Ovarian Cancer Trial.
    Mazzilli KM; McClain KM; Lipworth L; Playdon MC; Sampson JN; Clish CB; Gerszten RE; Freedman ND; Moore SC
    J Nutr; 2020 Apr; 150(4):694-703. PubMed ID: 31848620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.